Introduction
In the modern era, a pathology report requires the inclusion of numerous prognostically relevant histopathological tumour characteristics. Thyroid carcinoma is no exception to such rules. In addition to tumour type, variant and size, other features such as the presence and extent of capsular invasion (CI), vascular invasion (VI) and extrathyroidal extension (ETE) and margin status, as well as the number and size of neck lymph node(s) with metastatic carcinoma, have been shown to provide additional prognostic information, and are now required in a standardised pathology report for thyroid carcinoma, 1 and in the initial risk stratification published by several renowned organisations, e.g. the American Thyroid Association (ATA), the National Comprehensive Cancer Network (NCCN) and the American Joint Committee for Cancer (AJCC) staging manual, to guide management and determine the need for radioactive iodine (RAI) ablation therapy. [2] [3] [4] Hence, it becomes increasingly important for pathologists to report these parameters and for clinicians to understand the potential impacts of such on patient management. The current review intends to summarise the definition, diagnostic challenges, controversies and the clinical impacts of each pathological parameter which is incorporated into a routine pathology report of differentiated follicular-derived carcinoma.
Extrathyroidal extension
Extrathyroidal extension, defined as tumour extension beyond the thyroid capsule into the adjacent soft tissue, is a common pathological finding, detected in 23.5% of all papillary thyroid carcinomas. 5 ETE has long been considered as an adverse prognostic factor with an increased risk of recurrence and mortality. [5] [6] [7] [8] It can be subdivided further into two categories: (i) minimal (or microscopic) ETE, which is invasion into the immediate perithyroidal soft tissue, detected solely at microscopic level and not appreciated clinically or grossly at the time of surgery; and (ii) extensive (or gross) ETE that is defined as gross direct extension of the carcinoma into strap muscles (e.g. sternohyoid, sternothyroid, thyrohyoid and omohyoid muscles), subcutaneous tissue, adjacent viscera (e.g. larynx, trachea and oesophagus) or recurrent laryngeal nerve, and is typically established clinically by imaging or during the operation (Figure 1 ). These two categories of ETE bear different prognostic values: the risk of recurrence associated with minor ETE is approximately 3-9%, [9] [10] [11] [12] [13] [14] [15] compared with a 23-40% risk of recurrence in patients with gross ETE. 9, 10, [12] [13] [14] 16, 17 Furthermore, several recent studies have shown that microscopic ETE is not an independent predictor for persistent disease, recurrence-free survival and disease-specific survival (Figure 2) . 11, 12, 15, [17] [18] [19] Under the 2015 ATA guidelines, microscopic ETE is considered as a feature for intermediate-risk lesions which may be subjected to postoperative RAI treatment, while tumours with gross ETE are defined as high-risk lesions, thus mandating a (near-)total thyroidectomy and postoperative RAI therapy. 2 Similarly, NCCN 2017 guidelines recommend completion thyroidectomy and postoperative RAI for lesions with gross ETE, while the administration of 30 mCi of 131 I is considered optional for patients with a primary tumour of <4 cm, clinical M0 and minor ETE. Histologically, the thyroid gland is devoid of a welldefined capsule in many areas along its periphery, and the follicles are often intermingled with adipose tissue or even skeletal muscle. 20 Therefore, the very definition of microscopic ETE is problematic and subjective, and a universally accepted pathological criterion for ETE is lacking. In a recent study involving 11 expert endocrine pathologists, the following histological diagnostic criteria have been utilised and recognised as microscopic ETE: perithyroidal fat involvement by nine of 11 pathologists; perithyroidal skeletal muscle involvement by 11 of 11 pathologists, perithyroidal nerve involvement by nine of 11 pathologists and perithyroidal thick-wall vessel involvement by seven of 11 pathologists. Additionally, in tumours arising from the isthmus, three of 11 pathologists did not consider involvement of skeletal muscle as evidence of microscopic ETE. 21 Not surprisingly, the interobserver agreement for minimal ETE was poor, with a kappa value of 0.14 even among expert pathologists. 21 In the seventh edition of the AJCC staging system, a tumour with minimal ETE is staged as pT3 regardless of tumour size, while gross ETE beyond strap muscles is staged as T4 disease. 22 That microscopic ETE is associated with poor interobserver agreement and does not affect recurrence and survival raises concerns of whether microscopic ETE alone is sufficient to upstage a patient as pT3. Therefore, in the upcoming AJCC eighth edition, which will be implemented on 1 January 2018, microscopic ETE has been removed entirely from the staging system of differentiated thyroid carcinoma. 4 Gross ETE invading strap muscles only by a tumour of any size will be staged as pT3b, while gross ETE with invasion into subcutaneous soft tissue, larynx, trachea, oesophagus or recurrent laryngeal nerve as pT4a.
In summary, recent evidence has shown that microscopic or minimal ETE bears limited prognostic significance (i.e. does not impart worse outcome than absence of ETE), and may not be a reproducible histological feature. In comparison, carcinomas with gross ETE are associated with high risk of recurrence, and are considered as high-stage (at least pT3) and highrisk lesions which should trigger additional therapy, e.g. completion thyroidectomy and postoperative RAI. Therefore, it is crucial for the pathologists and clinicians to realize the difference between microscopic and gross ETE. A knee-jerk response from clinicians to consider completion thyroidectomy and postoperative RAI to a pathological report mentioning microscopic ETE only may subject the patient to unnecessary treatment, especially in PTC cases. 19 
Margin assessment
The margin status of a surgical resection for differentiated thyroid carcinoma is a mandatory reporting element in the current College of American Pathologists (CAP) guidelines, 1 and can be divided into three categories: an R0 resection (microscopically negative margin), an R1 resection (grossly complete resection with microscopically positive margin) and an R2 resection (grossly positive margin or incomplete resection). 4 Histologically, a positive margin is defined by the presence of tumour cells at the inked tissue border and/or the outer aspect of the thyroid gland ( Figure 3) . [23] [24] [25] [26] The reported frequency of microscopically positive margin is between 6.1% and 14.1%. [23] [24] [25] [26] Several recent studies have shown that a microscopically positive margin is not an independent predictor for recurrence and disease-free survival, especially after adjusting for tumour stage and ETE. [24] [25] [26] Taking these into consideration, the current ATA guideline has only included incomplete R2 resection into the risk stratification as a feature of high-risk lesions. 2 In contrast, the NCCN 2017 guideline has included any positive resection margin as one of the criteria along with large tumour (>4 cm), gross ETE, macroscopic nodal metastasis, macroscopic multifocal disease and VI to recommend completion thyroidectomy. predictor for recurrence-free survival with a 23-fold risk of recurrence, while a positive anterior margin did not pose a significant risk for recurrence. 24 Hence, it may be prudent to ink the anterior and posterior margins differently when processing thyroid specimens in pathology laboratories and to document the status of anterior and posterior margins separately in the pathology report.
Characteristics of regional nodal metastases
Regional lymph node metastasis is a common finding in papillary thyroid carcinoma, being detected in up to 80% of patients as a result of extensive neck dissection and meticulous histological examination. 27 Most studies have shown that regional nodal metastasis, especially lateral neck nodal disease, carries prognostic significance. 4, [27] [28] [29] [30] [31] The impact of nodal metastases on disease-specific and recurrence-free survival is relatively small, and is most evident in older patients. [29] [30] [31] Nodal metastases are incorporated into the AJCC tumour, nodal disease and distant metastasis (TNM) staging and prognostic stage group, and can be divided further into central (pN1a) and lateral compartment involvement (pN1b). 4, 28 Recently, increasing evidence has shown that various characteristics of nodal metastases, e.g. number, size and extranodal extension (ENE), may provide additional prognostic information. Thus, detailed features of nodal disease should be included in the pathology report, and be considered in the risk stratification and staging system. 18, 27, [32] [33] [34] [35] [36] [37] [38] A recent meta-analysis by Randolph et al. has shown that small-volume subclinical microscopic pathological N1 disease, i.e. five or fewer subcentimetre metastatic lymph nodes, conveys little prognostic impact on recurrence-free and disease-specific survival in PTC, compared with clinically evident macroscopic nodal disease involving more than five lymph nodes, especially those with ENE. 27 Taking these data into consideration, the NCCN 2017 guidelines no longer recommend completion thyroidectomy and postoperative RAI in small-volume pN1a disease, i.e. <5 involved nodes with metastasis <2 mm in the largest dimension. 3 Histological features of the nodal metastasis that have been incorporated into the ATA initial risk stratifications included the number of involved lymph nodes (>5 is considered as intermediate risk) and size of the metastatic lymph nodes (≥3 cm as high risk).
Extranodal extension is not an uncommon finding, being reported in up to 12% of PTC overall and 33% of nodal metastatic PTC. 18, 35 Similar to ETE, a welldefined consensus histological diagnostic criterion for ENE is currently lacking.
1,39 A recent study by Du et al. has shown that involvement of perinodal adipose tissue appears to be the most consistent diagnostic criteria of ENE, being considered by 11 participating endocrine pathologists as ENE. 39 However, the overall agreement in diagnosing ENE is only fair, with a kappa value of 0.35 among expert pathologists. 39 Nevertheless, studies have demonstrated repeatedly the association between ENE and persistent and/or recurrence disease. 18, 27, [32] [33] [34] [35] [36] [37] Hence, it is important to document ENE in the pathology report of a differentiated thyroid carcinoma.
Taken these recent data into consideration, the upcoming AJCC 8th edition has recommended recording detailed histological features of nodal metastasis in the pathological report, including number of involved lymph nodes, number of lymph nodes sampled, location of the involved lymph nodes, size of the largest involved lymph node, size of metastatic foci within involved lymph node and the presence of ENE. 4 
Vascular invasion
Vascular invasion was first described in thyroid malignancy by Graham 40 in 1924. Although three groups have shown that the mere existence of VI, regardless of the extent, entails a substantial risk of distant metastasis, a larger body of literature has shown that the extent (rather than the existence) of VI is a prognostic factor in low-grade thyroid carcinomas. [41] [42] [43] [44] [45] [46] Based on these studies, the current ATA and NCCN guidelines, as well as the upcoming 4th edition of the WHO classification, have advocated to separate encapsulated follicular and Hurthle cell carcinoma with extensive VI from those with CI only and/or focal (a few foci) of VI. 3, 47, 48 Tumours with minimal VI (defined as a few microscopic foci by NCCN, or fewer than five foci by ATA guidelines) are associated with a low risk of recurrence (0-5%) with an overall similar outcome to those without VI in low-grade thyroid carcinoma. [41] [42] [43] [44] [45] Fortunately, extensive VI appears to be a relatively rare event in differentiated thyroid carcinoma, being present in 8.7% of well-differentiated encapsulated thyroid carcinomas in one study. 45 When it occurs, extensive VI is an independent predictor of recurrence, is associated with a 42% risk of distant metastasis, and is observed frequently in patients who died of thyroid carcinoma. 17, 42, 45, 49 Based on this emerging evidence, the most recent ATA guidelines have classified an intrathyroidal follicular thyroid carcinoma with minimal VI as a low-risk lesion, which does not command a completion thyroidectomy and RAI ablation therapy. 2 Similarly, the NCCN 2017 guidelines have defined minimal VI as a few (one to four) foci of VI, and does not mandate RAI administration in an intrathyroidal well defined follicular or Hurthle cell carcinoma with minimal VI. 3 Conversely, the presence of extensive VI (>4 foci) in a differentiated thyroid carcinoma will place the patient into the high-risk group, which mandates total thyroidectomy and postoperative RAI therapy. 2, 3 In Hurthle cell carcinoma, tumours with extensive VI (≥4 foci) or extrathyroidal VI were associated with a different RNA expression profile compared with minimally invasive Hurthle cell carcinoma, including those with focal VI (<4 foci), suggesting that the molecular signatures might be different according to the extent of VI. 50 Hence, it is crucial for pathologists to evaluate and report the presence and extent of VI reliably in low-grade thyroid carcinoma in order to direct risk stratification and subsequent clinical treatment decisions.
However, the very definition of VI has been surrounded by controversies. The initial definition of VI delineated in the authorative 1992 and 2015 AFIP fascicles 51, 52 and adopted in the majority of the published literature mandated the following two conditions to be qualified for VI: (i) the involved blood vessels has to be located within or outside the tumour capsule; and (ii) the intravascular polypoid tumour growth must be attached to the vessel wall, admixed with fibrin or covered by endothelium (Figure 4) . Areas of VI that are closely adjacent to one another are counted typically as separate foci. 45 Conversely, a recent study published by Mete and Asa did not consider tumour protrusion into vascular space lined by endothelial cells alone as a diagnostic criterion for VI, but rather required fibrin thrombus adherent to intravascular tumour. 53 This is based on the idea that intravascular endothelial lined tumour is separated from the bloodstream by endothelial cells, while thrombus formation is indicative of host response and coagulation pathway activation. 53 When this more stringent criterion of VI is applied, the incidence of VI in differentiated thyroid carcinoma decreased drastically from 7-62% 45, 46, [54] [55] [56] to 3%, 53 while the risk of distant metastasis in association with the mere existence of VI becomes 35%. This latter approach may fail to identify a significant proportion of thyroid tumours with VI, focal or extensive, that should be classified as carcinoma based on the presence of invasion, and that may benefit from appropriate risk stratification and/or additional therapies.
Capsular invasion
The CAP guidelines and AFIP fascicle define CI as a tumour that completely transgressed the tumour capsule beyond the outer contour with or without neocapsule formation or satellite nodule lying outside the tumour capsule ( Figure 5) . 1, 52 Some authorities have advised using the term 'minimally invasive' to describe those carcinomas with microscopic CI only (regardless of number of CI foci), as their metastatic rate is close to 0. 44, 45, [57] [58] [59] [60] In contrast, widely invasive follicular carcinoma was used for carcinoma with grossly apparent invasion into the thyroid and perithyroidal soft tissue (i.e. ETE) 1 and is associated with a high risk of distant metastasis. 61 The existence of invasion, including CI, is the histological characteristic which distinguishes and differentiates certain types of malignant thyroid tumours from their non-malignant counterparts, e.g. follicular carcinoma from follicular adenoma, Hurthle cell carcinoma from Hurthle cell adenoma, as well as encapsulated follicular variant of papillary thyroid carcinoma with invasion from non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). 62 However, as multiple studies have shown that carcinomas with only CI, regardless of extent, is associated with an overall excellent prognosis, 43, 45, 57, [63] [64] [65] CI was not a factor being considered in risk stratification in ATA and NCCN guidelines.
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Conclusions
The field of thyroid pathology has evolved dramatically during the past several decades. Several major changes have occurred, including incorporation of numerous detailed pathological characteristics (e.g. the presence and extent of VI and ETE) into the pathology report. These shifts in the characterisation of thyroid carcinoma have led to the refining of risk stratification and de-escalation of therapy in differentiated thyroid carcinoma. The prognosis and therapy of thyroid carcinomas can be delineated more clearly if a meticulous microscopic analysis is performed. An accurate assessment of the extent of VI for example is crucial. Hence, it is important for pathologists to report meticulously on histopathological features other than tumour type, such as extent of invasion, in order to predict tumour spread and survival more accurately and assist clinical decision-making.
